Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.72 |
| ▸ | CPB1 | P15086 | 1/20 | 0.66 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.66 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.64 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGAV | P06756 | 1/20 | 0.60 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14157482 | 1.00 | FOLH1 (0.72) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL18907028 | 1.00 | FOLH1 (0.72) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL18907025 | 1.00 | FOLH1 (0.72) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL14157462 | 1.00 | FOLH1 (0.72) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL8641871 | 0.98 | FOLH1 (0.69) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL14519208 | 0.98 | FOLH1 (0.69) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL464715 | 0.95 | FOLH1 (0.78) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL806151 | 0.95 | FOLH1 (0.78) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL4561005 | 0.95 | FOLH1 (0.78) | FOLH1CPB1CPB2SIRT1SIRT2 | |
| SCHEMBL21019116 | 0.94 | FOLH1 (0.66) | FOLH1CPB1CPB2SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3980052-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020247297-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-2998289-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20180297938-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP | 2018-10-18 | — | — | US | disclosed |
| US-10100004-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-10-16 | — | — | US | disclosed |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2998289-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-2718261-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20160015656-A2 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2718261-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | Nitto Denko Corporation (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | NITTO DENKO CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | FOLH1 410/4885CPB1 1238/4885CPB2 1993/4885 |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, IRS1, INSR | FOLH1 410/4885CPB1 1238/4885CPB2 1993/4885 |
| US-20180297938-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | FOLH1 783/4885CPB1 3859/4885CPB2 4199/4885 |
| US-20160015656-A2 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | COL1A1, COL2A1, COL14A1 | FOLH1 1251/4885CPB1 862/4885CPB2 900/4885 |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | KIT, STRA6, HAVCR2 | FOLH1 513/4885CPB1 1576/4885CPB2 1840/4885 |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | FOLH1 783/4885CPB1 3859/4885CPB2 4199/4885 |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | FOLH1 783/4885CPB1 3859/4885CPB2 4199/4885 |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | COL1A1, COL2A1, COL14A1 | FOLH1 1251/4885CPB1 862/4885CPB2 900/4885 |
| US-10100004-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | FOLH1 783/4885CPB1 3859/4885CPB2 4199/4885 |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | FOLH1 783/4885CPB1 3859/4885CPB2 4199/4885 |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | FGFR2, FRS2, FOLR1 | FOLH1 45/4885CPB1 3248/4885CPB2 3038/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | FOLH1 2079/4885CPB1 4342/4885CPB2 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.